Medical marijuana licenses; authorizing certain research license; requiring promulgation of certain rules. Effective date.

SB 1822 creates a new research license for the Oklahoma Medical Marijuana Authority to study patient-reported outcomes related to medical marijuana use. It authorizes research institutions, healthcare organizations, licensed cannabis businesses, and private research companies to conduct studies on how medical marijuana affects health conditions. Licensees must pay a $500 nonrefundable fee, and the Authority must establish rules for licensing, compliance, and reporting. The bill takes effect November 1, 2026, and focuses solely on enabling research, not expanding patient access or product availability.